JP2016006125A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016006125A5 JP2016006125A5 JP2015196105A JP2015196105A JP2016006125A5 JP 2016006125 A5 JP2016006125 A5 JP 2016006125A5 JP 2015196105 A JP2015196105 A JP 2015196105A JP 2015196105 A JP2015196105 A JP 2015196105A JP 2016006125 A5 JP2016006125 A5 JP 2016006125A5
- Authority
- JP
- Japan
- Prior art keywords
- glp
- ala
- analog
- intestinal
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67806605P | 2005-05-04 | 2005-05-04 | |
| US60/678,066 | 2005-05-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013077830A Division JP5876434B2 (ja) | 2005-05-04 | 2013-04-03 | グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016006125A JP2016006125A (ja) | 2016-01-14 |
| JP2016006125A5 true JP2016006125A5 (https=) | 2016-03-10 |
| JP6272284B2 JP6272284B2 (ja) | 2018-01-31 |
Family
ID=36649773
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008509505A Active JP5405105B2 (ja) | 2005-05-04 | 2006-05-04 | グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ |
| JP2013077830A Expired - Fee Related JP5876434B2 (ja) | 2005-05-04 | 2013-04-03 | グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ |
| JP2015196105A Active JP6272284B2 (ja) | 2005-05-04 | 2015-10-01 | グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008509505A Active JP5405105B2 (ja) | 2005-05-04 | 2006-05-04 | グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ |
| JP2013077830A Expired - Fee Related JP5876434B2 (ja) | 2005-05-04 | 2013-04-03 | グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US7563770B2 (https=) |
| EP (4) | EP1877435B2 (https=) |
| JP (3) | JP5405105B2 (https=) |
| KR (3) | KR101200227B1 (https=) |
| CN (2) | CN101171262B (https=) |
| AT (1) | ATE498631T1 (https=) |
| AU (1) | AU2006242998B2 (https=) |
| BR (1) | BRPI0610091B1 (https=) |
| CA (1) | CA2607150C (https=) |
| CY (1) | CY1111411T1 (https=) |
| DE (1) | DE602006020123D1 (https=) |
| DK (1) | DK1877435T4 (https=) |
| EA (1) | EA014184B1 (https=) |
| ES (1) | ES2361095T5 (https=) |
| IL (3) | IL186746A (https=) |
| MX (1) | MX2007013431A (https=) |
| NO (1) | NO345236B1 (https=) |
| NZ (4) | NZ591178A (https=) |
| PL (1) | PL1877435T5 (https=) |
| PT (1) | PT1877435E (https=) |
| SI (1) | SI1877435T2 (https=) |
| UA (1) | UA95235C2 (https=) |
| WO (1) | WO2006117565A2 (https=) |
| ZA (2) | ZA200709384B (https=) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| WO2003103475A2 (en) | 2002-06-07 | 2003-12-18 | Dyax Corp. | Prevention and reduction of blood loss |
| JP2005537006A (ja) | 2002-08-28 | 2005-12-08 | ダイアックス、コープ | 臓器及び組織の保存方法 |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| DE602006020123D1 (de) * | 2005-05-04 | 2011-03-31 | Zealand Pharma As | Glucagon-like-peptide-2- (glp-2-) analoga |
| US20070213275A1 (en) * | 2006-03-10 | 2007-09-13 | Dyax Corp. | Formulations for ecallantide |
| JP5373606B2 (ja) * | 2006-07-26 | 2013-12-18 | サンド・アクチエンゲゼルシヤフト | カスポファンギン製剤 |
| WO2008031770A2 (en) * | 2006-09-12 | 2008-03-20 | Cosmo Technologies Ltd | Pharmaceutical compositions for the oral or rectal administration of protein substances |
| AU2007319066B2 (en) | 2006-11-08 | 2013-09-19 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (GLP-2) analogues |
| US20090004243A1 (en) | 2007-06-29 | 2009-01-01 | Pacetti Stephen D | Biodegradable triblock copolymers for implantable devices |
| KR20090035279A (ko) * | 2007-10-05 | 2009-04-09 | 경희대학교 산학협력단 | 위장관 손상 예방 및 치료용 조성물 |
| US20090110713A1 (en) * | 2007-10-31 | 2009-04-30 | Florencia Lim | Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices |
| CA2744235A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| CN101824087A (zh) * | 2009-03-05 | 2010-09-08 | 连云港恒邦医药科技有限公司 | 胰高血糖素样肽-2类似物及其制备方法和用途 |
| EP2314616A1 (en) * | 2009-10-23 | 2011-04-27 | Ferring B.V. | Peptidic GLP-2 agonists |
| EP3459564B1 (en) | 2010-01-06 | 2021-10-27 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
| ES2555164T3 (es) | 2010-08-30 | 2015-12-29 | Nps Pharmaceuticals, Inc. | Síntesis de fase sólida de h[Gly2]GLP-2 |
| CA2823776A1 (en) | 2011-01-06 | 2012-07-12 | Dyax Corp. | Plasma kallikrein binding proteins |
| CN102212127B (zh) * | 2011-05-17 | 2015-02-04 | 上海景泽生物技术有限公司 | 胰高血糖素样肽-2聚乙二醇结合物及其制备方法和用途 |
| CN102924589B (zh) * | 2011-08-11 | 2016-08-24 | 中肽生化有限公司 | 胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途 |
| EP2755675B1 (en) | 2011-09-12 | 2018-06-06 | Amunix Operating Inc. | Glucagon-like peptide-2 compositions and methods of making and using same |
| KR101895047B1 (ko) | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
| CN117462693A (zh) | 2012-02-27 | 2024-01-30 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| AU2013255752B2 (en) | 2012-05-03 | 2017-11-09 | Zealand Pharma A/S | Glucagon-like-peptide-2 (GLP-2) analogues |
| US20150038674A1 (en) * | 2013-08-05 | 2015-02-05 | Bayrak Bertan Boran | Use of glp-2 analogues in pulmonary diseases for therapeutic purpose |
| IL295414B2 (en) | 2014-03-27 | 2026-02-01 | Takeda Pharmaceuticals Co | Compositions and methods for treating macular edema due to diabetes |
| US20160067311A1 (en) * | 2014-09-10 | 2016-03-10 | Helsinn Healthcare Sa | Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea |
| US20170087216A1 (en) * | 2015-09-17 | 2017-03-30 | Helsinn Healthcare Sa | Therapeutic Uses of Elsiglutide |
| AU2016366557B2 (en) | 2015-12-11 | 2024-01-25 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| CN107987170B (zh) * | 2016-10-27 | 2018-12-18 | 浙江道尔生物科技有限公司 | 一种用于治疗肠道疾病的融合蛋白 |
| WO2018104558A1 (en) * | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| AU2017371516C1 (en) * | 2016-12-09 | 2021-09-02 | Zealand Pharma A/S | Acylated GLP-1/GLP-2 dual agonists |
| WO2018104559A1 (en) * | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Glp-1/glp-2 dual agonists |
| JP2020500890A (ja) * | 2016-12-09 | 2020-01-16 | ジーランド・ファーマ・ア／エス | Ｇｌｐ−１／ｇｌｐ−２二重アゴニスト |
| WO2018142363A1 (en) * | 2017-02-06 | 2018-08-09 | Orbicular Pharmaceutical Technologies Private Limited | Ready to use compositions of glp-2 analogues through self-administrable devices |
| BR112019026711A2 (pt) | 2017-06-16 | 2020-06-30 | Zealand Pharma A/S | regimes de dosagem para a administração de análogos de peptídeo semelhante a glucagon- 2 (glp-2) |
| CA3084326A1 (en) * | 2017-09-28 | 2019-04-04 | Jaehyuk Choi | Long-acting conjugates of glp-2 derivatives |
| WO2019086559A1 (fr) | 2017-10-31 | 2019-05-09 | Adocia | Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
| WO2020020904A1 (en) | 2018-07-23 | 2020-01-30 | Zealand Pharma A/S | Therapeutic uses of glp-2 agonists |
| EP3628682A1 (en) * | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| EP3628683A1 (en) * | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| EP3924369A1 (en) * | 2019-02-11 | 2021-12-22 | OPKO Biologics Ltd. | Long-acting glp-2 analogs |
| BR112021020941A2 (pt) | 2019-06-14 | 2021-12-21 | Zealand Pharma As | Composição farmacêutica parenteral isotônica, método para melhoria da estabilidade química da dita composição e uso de manitol |
| CN110305223B (zh) | 2019-06-26 | 2022-05-13 | 重庆派金生物科技有限公司 | 重组串联融合蛋白制备目标多肽的方法 |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| AU2020397917A1 (en) | 2019-12-04 | 2022-06-23 | The Scripps Research Institute | GLP2 receptor agonists and methods of use |
| US12528880B2 (en) | 2020-01-13 | 2026-01-20 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| IL295825A (en) | 2020-02-28 | 2022-10-01 | Kallyope Inc | gpr40 agonists |
| EP4126004A1 (en) | 2020-03-30 | 2023-02-08 | Zealand Pharma A/S | Agonist combination |
| EP4144361A4 (en) * | 2020-04-03 | 2024-05-22 | Hanmi Pharm. Co., Ltd. | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF MUCOSITIS INDUCED BY RADIOTHERAPY, CHEMOTHERAPY OR A COMBINATION THEREOF, WITH GLP-2 DERIVATIVES OR LONG-ACTING CONJUGATE THEREOF |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CN111560061A (zh) * | 2020-05-26 | 2020-08-21 | 成都圣诺生物制药有限公司 | 一种Gelpaglutide的制备方法 |
| CN111560062A (zh) * | 2020-05-26 | 2020-08-21 | 成都圣诺生物制药有限公司 | 一种Elisiglutide的制备方法 |
| KR20230038187A (ko) | 2020-06-09 | 2023-03-17 | 벡티브바이오 에이지 | 아프라글루타이드의 제조, 제형화 및 투여 |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| MX2023006901A (es) | 2020-12-16 | 2023-06-26 | Zealand Pharma As | Uso de analogos de glp-2 en pacientes con insuficiencia renal. |
| TW202241491A (zh) * | 2020-12-16 | 2022-11-01 | 丹麥商西蘭製藥公司 | Ｇｌｐ－１／ｇｌｐ－２雙重促效劑之醫藥組合物 |
| MX2023014771A (es) | 2021-06-09 | 2024-03-19 | Scripps Research Inst | Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso. |
| CN115636876A (zh) * | 2021-07-20 | 2023-01-24 | 重庆派金生物科技有限公司 | 胰高血糖素样肽-2突变体的定向化学偶联物及其应用 |
| AU2022341538A1 (en) | 2021-09-10 | 2024-04-11 | Zealand Pharma A/S | Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues |
| WO2023118416A1 (en) | 2021-12-23 | 2023-06-29 | Zealand Pharma A/S | Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues |
| EP4572783A1 (en) | 2022-09-30 | 2025-06-25 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs) |
| IL322328A (en) | 2023-01-27 | 2025-09-01 | Zealand Pharma As | Glucagon-like peptide-2 (GLP-2) analogs and their medical uses for the treatment of short bowel syndrome (SBS) |
| CN116478269A (zh) * | 2023-04-28 | 2023-07-25 | 成都奥达生物科技有限公司 | 一种长效替度鲁肽化合物 |
| CN116751278B (zh) * | 2023-06-21 | 2024-02-13 | 杭州信海医药科技有限公司 | 一种Glepaglutide的制备方法 |
| WO2025141129A1 (en) | 2023-12-28 | 2025-07-03 | Zealand Pharma A/S | Formulations of glucagon-like-peptide 2 (glp-2) analogues and their uses |
| WO2025162422A1 (zh) * | 2024-01-31 | 2025-08-07 | 杭州先为达生物科技股份有限公司 | 胰高血糖素样肽2衍生物及其应用 |
| WO2025181330A1 (en) | 2024-02-29 | 2025-09-04 | Vectivbio Ag | Dosage regimens for glucagon-like peptide 2 (glp-2) analogs |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| JP2961045B2 (ja) * | 1993-02-24 | 1999-10-12 | 日清製粉株式会社 | 腸管粘膜増強促進剤 |
| US6184208B1 (en) | 1994-06-29 | 2001-02-06 | Immunotech Developments Inc. | Peptide, a method for its preparation and a pharmaceutical composition containing the peptide |
| US5789379A (en) | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
| US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| DE69717092T2 (de) † | 1996-03-01 | 2003-07-24 | Novo Nordisk A/S, Bagsvaerd | Gebrauch einer pharmazeutischen Zusammensetzung, enthaltend ein appetitzügelndes Peptid |
| US5912229A (en) | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
| DE60142885D1 (de) * | 1996-04-12 | 2010-10-07 | Ontario Inc 1149336 | Dem Glukagon ähnliches Peptid-2 |
| US5994500A (en) | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
| US20020025933A1 (en) | 1996-08-30 | 2002-02-28 | Knudsen Liselotte Bjerre | GLP-2 derivatives |
| CZ295838B6 (cs) | 1996-09-09 | 2005-11-16 | Zealand Pharma A/S | Způsob výroby peptidů |
| US5952301A (en) * | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
| CA2236519C (en) | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| US6051557A (en) | 1997-05-16 | 2000-04-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the upper gastrointestinal tract |
| DK0981362T3 (da) † | 1997-05-16 | 2004-03-15 | Ontario Inc 1149336 | Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal |
| AU766219B2 (en) * | 1998-02-02 | 2003-10-09 | 1149336 Ontario Inc. | Method of regulating glucose metabolism, and reagents related thereto |
| JP4394279B2 (ja) | 1998-03-09 | 2010-01-06 | ジーランド ファーマ アクティーゼルスカブ | 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体 |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| WO2001041779A2 (en) | 1999-12-08 | 2001-06-14 | 1149336 Ontario Inc. | Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment |
| US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| ES2310192T3 (es) | 2000-09-18 | 2009-01-01 | Sanos Bioscience A/S | Uso de peptidos glp-2. |
| US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| WO2002066062A2 (en) | 2001-02-01 | 2002-08-29 | Drucker Daniel J | Enhancement of glp-2 activity |
| ATE396202T1 (de) | 2001-02-16 | 2008-06-15 | Conjuchem Biotechnologies Inc | Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen |
| US7144863B2 (en) * | 2001-06-01 | 2006-12-05 | Eli Lilly And Company | GLP-1 formulations with protracted time action |
| WO2004035624A2 (en) * | 2002-10-14 | 2004-04-29 | Novo Nordisk A/S | Glucagon - like peptide - 2 variants |
| WO2004085471A2 (en) * | 2003-03-24 | 2004-10-07 | Novo Nordisk A/S | Glp-2 derivatives |
| KR101241862B1 (ko) * | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| ES2427150T3 (es) * | 2004-11-01 | 2013-10-29 | Nps Pharmaceuticals, Inc. | Tratamiento de pacientes con el síndrome del intestino corto con colon en continuidad |
| DE602006020123D1 (de) | 2005-05-04 | 2011-03-31 | Zealand Pharma As | Glucagon-like-peptide-2- (glp-2-) analoga |
| AU2007319066B2 (en) * | 2006-11-08 | 2013-09-19 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (GLP-2) analogues |
| US8685919B2 (en) | 2008-12-15 | 2014-04-01 | Zealand Pharma A/S | Glucagon analogues |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| KR20240110072A (ko) | 2011-05-18 | 2024-07-12 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 제약 |
-
2006
- 2006-05-04 DE DE602006020123T patent/DE602006020123D1/de active Active
- 2006-05-04 MX MX2007013431A patent/MX2007013431A/es active IP Right Grant
- 2006-05-04 BR BRPI0610091-0A patent/BRPI0610091B1/pt active IP Right Grant
- 2006-05-04 DK DK06727006.6T patent/DK1877435T4/da active
- 2006-05-04 PL PL06727006T patent/PL1877435T5/pl unknown
- 2006-05-04 KR KR1020077028167A patent/KR101200227B1/ko active Active
- 2006-05-04 CN CN2006800152135A patent/CN101171262B/zh active Active
- 2006-05-04 CN CN201210124331.7A patent/CN102659938B/zh not_active Expired - Fee Related
- 2006-05-04 AU AU2006242998A patent/AU2006242998B2/en active Active
- 2006-05-04 PT PT06727006T patent/PT1877435E/pt unknown
- 2006-05-04 EP EP06727006.6A patent/EP1877435B2/en active Active
- 2006-05-04 EP EP10009232A patent/EP2295452A1/en not_active Withdrawn
- 2006-05-04 KR KR1020117015196A patent/KR101242795B1/ko not_active Expired - Fee Related
- 2006-05-04 ES ES06727006T patent/ES2361095T5/es active Active
- 2006-05-04 CA CA2607150A patent/CA2607150C/en active Active
- 2006-05-04 WO PCT/GB2006/001633 patent/WO2006117565A2/en not_active Ceased
- 2006-05-04 NZ NZ591178A patent/NZ591178A/en not_active IP Right Cessation
- 2006-05-04 NZ NZ562943A patent/NZ562943A/en not_active IP Right Cessation
- 2006-05-04 UA UAA200713558A patent/UA95235C2/ru unknown
- 2006-05-04 EP EP10009231A patent/EP2295451A1/en not_active Withdrawn
- 2006-05-04 EP EP18206332.1A patent/EP3473646A1/en active Pending
- 2006-05-04 NZ NZ591179A patent/NZ591179A/en not_active IP Right Cessation
- 2006-05-04 EA EA200702408A patent/EA014184B1/ru unknown
- 2006-05-04 SI SI200630985T patent/SI1877435T2/sl unknown
- 2006-05-04 KR KR1020117015195A patent/KR101242951B1/ko not_active Expired - Fee Related
- 2006-05-04 JP JP2008509505A patent/JP5405105B2/ja active Active
- 2006-05-04 NZ NZ593050A patent/NZ593050A/xx unknown
- 2006-05-04 AT AT06727006T patent/ATE498631T1/de active
- 2006-05-04 US US11/429,168 patent/US7563770B2/en active Active
- 2006-11-09 US US11/595,496 patent/US7745403B2/en active Active
-
2007
- 2007-10-18 IL IL186746A patent/IL186746A/en active IP Right Grant
- 2007-10-31 ZA ZA2007/09384A patent/ZA200709384B/en unknown
- 2007-11-23 NO NO20076043A patent/NO345236B1/no unknown
-
2009
- 2009-12-21 US US12/643,233 patent/US8263552B2/en active Active
- 2009-12-21 US US12/643,261 patent/US8163696B2/en active Active
-
2011
- 2011-01-16 IL IL210669A patent/IL210669A/en active IP Right Grant
- 2011-01-16 IL IL210668A patent/IL210668A/en active IP Right Grant
- 2011-01-28 ZA ZA2011/00753A patent/ZA201100753B/en unknown
- 2011-05-05 CY CY20111100436T patent/CY1111411T1/el unknown
-
2012
- 2012-06-28 US US13/536,377 patent/US9125882B2/en active Active
-
2013
- 2013-04-03 JP JP2013077830A patent/JP5876434B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-08 US US14/847,938 patent/US9580487B2/en active Active
- 2015-10-01 JP JP2015196105A patent/JP6272284B2/ja active Active
-
2017
- 2017-01-20 US US15/411,649 patent/US20170137487A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016006125A5 (https=) | ||
| JP2008539713A5 (https=) | ||
| ES2792848T3 (es) | Politerapia para el tratamiento de infecciones por VHB | |
| US10577337B2 (en) | Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof | |
| ES2772754T3 (es) | Pemafibrato para uso en el tratamiento de la enfermedad del hígado graso no alcohólico | |
| ES2647216T3 (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
| US10301255B2 (en) | Hepatitis B antiviral agents | |
| MX2022010044A (es) | Composicion farmaceutica que comprende microesferas de liberacion sostenida que incluyen analogo de glp-1 o sal farmaceuticamente aceptable del mismo. | |
| RU2020109881A (ru) | Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита | |
| JP2015518818A5 (https=) | ||
| EP3589628A1 (en) | Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders | |
| JP2014077003A5 (https=) | ||
| JP2008513506A5 (https=) | ||
| JPWO2019107530A5 (https=) | ||
| JP2011225596A5 (https=) | ||
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| JP2015535243A5 (https=) | ||
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2016510326A5 (https=) | ||
| EA201100565A1 (ru) | Композиции и способы лечения заболеваний кишечника с использованием гранулированного мезаламина | |
| JP2017514911A5 (https=) | ||
| RU2018123718A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| JP2016507500A5 (https=) | ||
| US20190070212A1 (en) | Compounds and compositions for the treatment of infections |